NETRF Recognized as Top-Tier Charity
NETRF’s strong financial position, transparency, and accountability again earned it a 4-star rating by Charity Navigator, a national evaluator of nonprofits. The 4-star rating indicates the utmost in fiscal responsibility, ethical practices, and governance.
News & Updates
Early Research on Targeting Single Cancer Cells to Prevent Metastasis Despite the effectiveness of Peptide Receptor Radionuclide Therapy (PRRT) to prolong survival of those with neuroendocrine tumors (NETs), many patients will see their cancer spread a
The Neuroendocrine Tumor Research Foundation (NETRF) gratefully received a $35,000 donation for NET research from the CarGurus Charitable Giving Fund. NETRF was nominated by a CarGurus employee to receive a grant and this grant was one
Antibody-drug conjugate aims to combine the benefits of targeted therapy and chemotherapy (Left to right) Elyse Gellerman, NETRF CEO; Renata Jaskula-Sztula, PhD, NANETS/NETRF BTSI Investigator; Effie Tzameli, PhD, NETRF Director of Research. Renata Jaskula-Sztul, PhD, Assistant